Kyowa Kirin was represented by Goldman Sachs Japan Co., Ltd. as financial advisor and Morrison & Foerster LLP. as legal advisor. Orchard Therapeutics was represented by...
Kyowa Kirin’s $387 Million Acquisition of Orchard Therapeutics
Lonza’s Acquisition of Synaffix
Bird & Bird advised Lonza, while Goodwin and NautaDutilh advised Synaffix. SynAffix B.V. announced the sale to Lonza Group AG. Under the terms of the sale and...
TCR² Therapeutics’ Agreement with Adaptimmune Therapeutics
Goodwin advised TCR² Therapeutics Inc. on the deal while Ropes & Gray represented Adaptimmune Therapeutics plc. TCR² Therapeutics Inc. (NASDAQ: TCRR) announced its definitive agreement with Adaptimmune...
Grey Wolf Therapeutics’ $49 Million Series B Funding Round
Goodwin Procter advised Grey Wolf Therapeutics on the deal, while DLA Piper advised Pfizer Ventures and Earlybird Venture Capital. Grey Wolf Therapeutics announced its $49 million Series B...
AbbVie’s Acquisition of Syndesi
Goodwin advised Syndesi Therapeutics on the deal. Deloitte Legal assisted the selling shareholders and the company with the sale of Syndesi Therapeutics. Syndesi annouunced its acquisition by...
Exscientia’s $510.4 Million IPO
Cooley LLP advised Exscientia on the deal while Goodwin Procter represented Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, BofA Securities and Barclays Capital...
Amryt Pharma’s Acquisition of Chiasma
Goodwin Procter LLP advised Chiasma, Inc. on the deal. Chiasma, Inc. (Nasdaq: CHMA) announced its definitive agreement to be acquired by Amryt Pharma plc (Nasdaq: AMYT, AIM:...
Vaccitech’s $110.5 Million Initial Public Offering
Goodwin Procter LLP advised Vaccitech on the deal, while Davis Polk advised the representatives of the several underwriters. Vaccitech (Nasdaq: VACC) announced its initial public offering...
Insightful Science’s Acquisition of Dotmatics
Goodwin Procter LLP advised Dotmatics, while Willkie Farr & Gallagher LLP advised Insightful Science on the deal. Insightful Science, a leading software provider serving the global...
Vaccitech’s $168 Million Series B Financing Round
Goodwin Procter LLP advised Vaccitech on the deal. Vaccitech announced the completion of its $168 million Series B, including the conversion of $43 million in convertible loan...